Change of the nature of dystonic hyperkinesis in patients suffering from spasmodic torticollis following recurrent injections of botulotoxin A


如何引用文章

全文:

详细

The data of the 6-year follow-up of 101 patients with spasmodic torticollis (ST) receiving regular treatment with botulotoxin type A (BTA) in Belarus are presented. The comparison group comprised 74 patients suffering from ST and receiving traditional therapy without BTA. Stable positive effect of BTA on repeat injections every 6–10 months was revealed. On this background, the amount of combined forms of ST, as well as the number of cases of retro- and laterokollis, increased, and a part of the patients displayed the «bayonet» symptom. Change in the head posture required changes in the selection of target muscles for BTA injection. Clinical example of high efficacy of longterm therapy with 8 consecutive injections is presented. Even with long intervals (9–18 months) between repeat BTA injections, the degree of ST severity did not reach the initial values.

 

作者简介

S. Likhachev

Republican Research and Practical Centre of Neurology and Neurosurgery, Minsk

编辑信件的主要联系方式.
Email: platonova@neurology.ru
白俄罗斯

T. Chernukha

Republican Research and Practical Centre of Neurology and Neurosurgery, Minsk

Email: platonova@neurology.ru
白俄罗斯

参考

  1. Лихачев С.А., Рушкевич Ю.Н., Веевник Е.В. и др. Фокальная мышечная дистония: этиология, патогенез, диагностика, лечение. Методическое пособие. Минск: Ольдевен, 2005.
  2. Орлова О.Р., Голубев В.П. Феномен инверсии ротации при спастической кривошее. Журн. неврол. и психиатрии им. С.С. Корсакова 1986; 3: 348–350.
  3. Орлова О.Р., Яхно Н.Н. Применение Ботокса (БТА) в клинической практике. М.: Каталог, 2000.
  4. Тимербаева С.Л. Ботулинестический токсин типа А (диспорт) – новое слово в клинической нейрофармакологии. Фарматека 2007; 17: 40–46.
  5. Шток В.Н., Иванова-Смоленская И.А., Левин О.С. (ред.) Экстрапирамидные расстройства: Руководство по диагностике и лечению. М.: МЕДпресссинформ, 2002.
  6. Albanese A. Update on dystonia. Teaching course 1.2. In: 10th Congress of the European Federation of Neurological Societies. Glasgow, Sept. 2–5, 2006: 1–17.
  7. Brin M.F., Hallett M., Jankovic J. Scientific and therapeutic aspects of botulinum toxic. N.Y.: Wilkins, 2002.
  8. Collaborative Group. The Epidemiological Study of Dystonia in Europe (ESDE). A prevalence study of primary dystonia in eight European countries. J. Neurol. 2000; 47: 787–792.
  9. Dressier D. Botulinum toxin therapy. Stuttgart: Thieme Verlag, 2000.
  10. Gelb D.J., Yoshimura D.M., Olney R.K. et al. Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann. Neurol. 1991; 29: 370–376.
  11. Haussermann P., Marczoch S., Klinger С. et al. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov. Disord. 2004; 19: 303–308.
  12. Homann C.N., Suppan K., Wenzel K. et al. East-west differences in the organization of botulinum toxin use in nine Central European countries. Eur. J. Neurol. 2003; 10: 213–219.
  13. Kessler K.R., Skutta M., Benecke R. Long-term treatment of cervical dystonia with botulinum toxin А: efficacy, safety and antibody frequency. J. Neurol. 1999; 6: 74–76.
  14. Zuber M., Sebald M., Bathien N. et al. Botulinum antibodies in distonic patients treated with type A botulinum toxin: frequency and significance. Neurology 1993; 43: 1715–1718.

版权所有 © Likhachev S.A., Chernukha T.N., 2008

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##